Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00003805CT.gov Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bone Marrow Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Piperacillin (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB · 64 |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Vancomycin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Tazobactam | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | B |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
| Treosulfan | Fred Hutchinson Cancer Center | P2 | B |
| Atorvastatin | Fred Hutchinson Cancer Center | P2 | B |
| Pelabresib | Constellation Pharmaceuticals | P1/2 | CCC |
+18 more in the Bone Marrow Disorder cohort
Other indications for Piperacillin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | — | P4 | BB · 65 |
| Respiratory Tract Infectious Disorder | — | P4 | BB · 65 |
| Pseudomonas Aeruginosa Infectious Disease | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Piperacillin in Bone Marrow Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/piperacillin-bone-marrow-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →